• Disease Description

    Alzheimer's disease is a fatal, progressive and degenerative disease that destroys brain cells. It is the most common form of dementia, accounting for 64 per cent of all dementias.


    Alzheimer's disease is not a normal part of aging. Symptoms include having difficulty remembering things, making decisions and performing everyday activities. These changes can affect the way a person feels and acts.


    Alzheimer’s typically appears after the age of 60. We do not yet know what causes Alzheimer's disease but researchers have identified risk factors including aging, genetics, existing disease and infections among others. -Alzheimer Society of Canada


    Prevalence


    Alzheimer’s is the most common form of dementia in the United States, affecting 5.4 million Americans.


    Current Treatment


    There is currently no way to stop the disease, but research is improving the way we provide care and will continue to search for a cure.


    Evidence for and Proposed Mechanism of Cannabinoid Therapeutics


    In a study entitled "Alzheimer’s disease; taking the edge off with cannabinoids?" at Department of Physiology and Trinity College Institute of Neuroscience in Dublin, Ireland, it’s reported that "In brains obtained from Alzheimer’s patients, alterations in components of the cannabinoid system have been reported, suggesting that the cannabinoid system either contributes to, or is altered by, the pathophysiology of the disease." The study goes on to say, "cannabinoids offer a multi-faceted approach for the treatment of Alzheimer’s disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain’s intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis." Another study entitled "A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology" at the Department of Chemistry and Immunology, The Skaggs Institute for Chemical Biology in California, claimed, "Compared to currently approved drugs prescribed for the treatment of Alzheimer's disease, THC is a considerably superior inhibitor of Abeta aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease."

  • Category
    Critical Ailments
  • Created
    Thursday, 16 March 2017
  • Group admin
    CBIS

Cannabis Science Share Structure Updates

CBIS Share Structure Updates

Cannabis Science Updates

CBIS Updates

Transfer Agent

Securities Transfer Corp.

STC is regulated by the Securities and Exchange Commission

2901 N Dallas Parkway
Suite 380
Plano, Texas 75093
(469) 633-0101

Become an iCannabinoid Ambassador

GET INV

Observational Studies

PART

Activity Stream

Raymond,
Would it be possible for you or maybe a designee to send out an update once a week? Maybe certain day and time? Ex.: every Friday noon,...
Show more

Tim W. H. Mr. Dabney, know you're busy, time is short to 1st qtr 2020, but we had hoped a weekly, Friday update would show up on the company website. Doesn't... Show more yesterday
loader
loader
Attachment
Raymond C. Dabney I think everyone is still digesting all the last round of information. As we proceed with updates that are timely we will announce them.

Otherwise we are...
Show more
19 hours 2 minutes ago
loader
loader
Attachment
wenying yan Mr. Dabney, I am wondering if we can purchase class A shares for our SEP IRA contribution..... 5 hours 3 minutes ago
loader
loader
Attachment

Notifications

Events

Sorry, we currently have no events.
View All Events